Costs in different states of prostate cancer

References

• Bray F, Ren JS, Masuyer E, Ferlay J. Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133–45.
   PubMed Web of Science ®Google Scholar
• Piper NY, Kusada L, Lance R, Foley J, Moul J, Seay T. Adenocarcinoma of the prostate: An expensive way to die. Prostate Cancer Prostatic Dis 2002;5:164–6.
   PubMed Web of Science ®Google Scholar
• Torvinen S, Färkkilä N, Sintonen H, Saarto T, Roine RP, Taari K. Health-related quality of life in prostate cancer. Acta Oncol 2013;52:1094–101.
   PubMed Web of Science ®Google Scholar
• Färkkilä N, Torvinen S, Roine RP, Sintonen H, Hänninen J, Taari K, et al. Health-related quality of life among breast, prostate, and colorectal cancer patients with end-stage disease. Qual Life Res 2014;23:1387–94.
   PubMed Web of Science ®Google Scholar
• Hanly P, Timmons A, Walsh PM, Sharp L. Breast and prostate cancer productivity costs: A comparison of the human capital approach and friction cost approach. Value in Health 2012;15:429–36.
   PubMed Web of Science ®Google Scholar
• Hujanen T, Kapiainen S, Tuominen U, Pekurinen M. Terveydenhuollon yksikkökustannukset Suomessa vuonna 2006. Helsinki: Stakesin työpapereita 3/2008. [cited 10.8.2014]. Available from: https://www.julkari.fi/bitstream/handle/10024/76754/T3–2008-VERKKO.pdf?sequence = 1.
   Google Scholar
• Hoefman RJ, van Exel J, Brouwer W. How to include informal care in economic evaluations. Pharmacoeconomics 2013;31:1105–19.
   PubMed Web of Science ®Google Scholar
• Statistics Finland. Official statistics of Finland. Structure of earnings 2010. 2011. Statistics of Finland. [cited 10.8.2014]. Available from: http://www.stat.fi.
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality- of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76.
   PubMed Web of Science ®Google Scholar
• Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A, et al. The EORTC QLQ-C30 scoring manual, 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
   Google Scholar
• Statistical Package for the Social Sciences [computer program]. Version 21, 2012.
   Google Scholar
• Kalseth J, Halsteinli V, Halvorsen T, Kalseth B, Anthun K, Peltola M, et al. Cost of cancer in Nordic countries: A comparative study of health care costs and public income loss compensation payments related to cancer in the Nordic countries in 2007; 2011. [cited 10.10.2014]. Available from: http://www.ncu.nu.
   Google Scholar
• Sanyal C, Aprikian AG, Chevalier S, Cury FL, Dragomir A. Direct cost for initial management of prostate cancer: A systematic review. Curr Oncol 2013;20:522–31.
   Web of Science ®Google Scholar
• Brown MI, Lipscomb J, Snyder C. The burden of illness of cancer: Economic cost and quality of life. Annu Rev Public Health 2001;22:91–113.
   PubMed Web of Science ®Google Scholar
• Yabroff KR, Davis WW, Lamont EB, Fahey A, Topor M, Brown ML, et al. Patient time costs associated with cancer care. J Natl Cancer Inst 2007;99:14–23.
   PubMed Web of Science ®Google Scholar
• Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, Brown ML. Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst 2008; 100:1763–70.
   PubMed Web of Science ®Google Scholar
• Lidgren M, Wilking N, Jönsson B. Cost of breast cancer in Sweden in 2002. Eur J Health Econ 2007;8:5–15.
   PubMed Web of Science ®Google Scholar
• Jayadevappa R, Schwartz JS, Chhatre S, Gallo JJ, Wein AJ, Malkowicz SB. The burden of out-of-pocket and indirect costs of prostate cancer. Prostate 2010;70: 1255–64.
   PubMed Web of Science ®Google Scholar
• Mehra M, Wu Y, Dhawan R. Healthcare resource use in advanced prostate cancer patients treated with docetaxel. J Med Econ 2012;15:836–43.
   PubMedGoogle Scholar
• Färkkilä N, Torvinen S, Sintonen H, Saarto T, Järvinen H, Hänninen J, et al. Costs of colorectal cancer in different states of disease. Acta Oncol Epub 2014 Dec 18:1–9.
   Google Scholar
• Krol M, Papenburg J, Koopmanschap M, Brouwer W. Do productivity costs matter? The impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders. Pharmacoeconomics 2011; 29:601–19.
   Google Scholar
• Hoefman RJ, van Excel J, Brouwer W. How to include informal care in economic evaluations. Pharmacoeconomics 2013;31:1105–19.
   PubMed Web of Science ®Google Scholar